Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Pick a location for the injection
[8] Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, [9] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment
This information will be critical for patients, clinicians and policymakers to make informed decisions on the use of this important class of medications. 2
Research shows patients on GLP-1 therapy tolerate low-fat proteins and lean meats significantly better
US$ 22.78
US$ 28.98
US$ 27.59
